Cargando…
Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer
Blood methylated cell-free DNA (cfDNA) as a minimally invasive cancer biomarker has great importance in cancer management. Guanylate binding protein 2 (GBP2) has been considered as a possible controlling factor in tumor development. GBP2 gene expression and its promoter methylation status in both pl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Genética
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783727/ https://www.ncbi.nlm.nih.gov/pubmed/33211060 http://dx.doi.org/10.1590/1678-4685-GMB-2019-0230 |
_version_ | 1783632167662780416 |
---|---|
author | Rahvar, Farzaneh Salimi, Mahdieh Mozdarani, Hossein |
author_facet | Rahvar, Farzaneh Salimi, Mahdieh Mozdarani, Hossein |
author_sort | Rahvar, Farzaneh |
collection | PubMed |
description | Blood methylated cell-free DNA (cfDNA) as a minimally invasive cancer biomarker has great importance in cancer management. Guanylate binding protein 2 (GBP2) has been considered as a possible controlling factor in tumor development. GBP2 gene expression and its promoter methylation status in both plasma cfDNA and tumor tissues of ductal carcinoma breast cancer patients were analyzed using SYBR green comparative Real-Time RT-PCR and, Methyl-specific PCR techniques, respectively in order to find a possible cancer-related marker. The results revealed that GBP2 gene expression and promoter methylation were inversely associated. GBP2 was down-regulated in tumors with emphasis on triple negative status, nodal involvement and higher cancer stages (p<0.0001). GBP2 promoter methylation on both cfDNA and tumor tissues were positively correlated and was detected in about 88% of breast cancer patients mostly in (Lymph node positive) LN+ and higher stages. Data provided shreds of evidence that GBP2 promoter methylation in circulating DNA may be considered as a possible effective non-invasive molecular marker in poor prognostic breast cancer patients with the evidence of its relation to disease stage and lymph node metastasis. However further studies need to evaluate the involvement of GBP2 promoter methylation in progression-free survival or overall survival of the patients. |
format | Online Article Text |
id | pubmed-7783727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Sociedade Brasileira de Genética |
record_format | MEDLINE/PubMed |
spelling | pubmed-77837272021-01-14 Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer Rahvar, Farzaneh Salimi, Mahdieh Mozdarani, Hossein Genet Mol Biol Human and Medical Genetics Blood methylated cell-free DNA (cfDNA) as a minimally invasive cancer biomarker has great importance in cancer management. Guanylate binding protein 2 (GBP2) has been considered as a possible controlling factor in tumor development. GBP2 gene expression and its promoter methylation status in both plasma cfDNA and tumor tissues of ductal carcinoma breast cancer patients were analyzed using SYBR green comparative Real-Time RT-PCR and, Methyl-specific PCR techniques, respectively in order to find a possible cancer-related marker. The results revealed that GBP2 gene expression and promoter methylation were inversely associated. GBP2 was down-regulated in tumors with emphasis on triple negative status, nodal involvement and higher cancer stages (p<0.0001). GBP2 promoter methylation on both cfDNA and tumor tissues were positively correlated and was detected in about 88% of breast cancer patients mostly in (Lymph node positive) LN+ and higher stages. Data provided shreds of evidence that GBP2 promoter methylation in circulating DNA may be considered as a possible effective non-invasive molecular marker in poor prognostic breast cancer patients with the evidence of its relation to disease stage and lymph node metastasis. However further studies need to evaluate the involvement of GBP2 promoter methylation in progression-free survival or overall survival of the patients. Sociedade Brasileira de Genética 2020-11-17 /pmc/articles/PMC7783727/ /pubmed/33211060 http://dx.doi.org/10.1590/1678-4685-GMB-2019-0230 Text en https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Human and Medical Genetics Rahvar, Farzaneh Salimi, Mahdieh Mozdarani, Hossein Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer |
title | Plasma GBP2 promoter methylation is associated with
advanced stages in breast cancer |
title_full | Plasma GBP2 promoter methylation is associated with
advanced stages in breast cancer |
title_fullStr | Plasma GBP2 promoter methylation is associated with
advanced stages in breast cancer |
title_full_unstemmed | Plasma GBP2 promoter methylation is associated with
advanced stages in breast cancer |
title_short | Plasma GBP2 promoter methylation is associated with
advanced stages in breast cancer |
title_sort | plasma gbp2 promoter methylation is associated with
advanced stages in breast cancer |
topic | Human and Medical Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783727/ https://www.ncbi.nlm.nih.gov/pubmed/33211060 http://dx.doi.org/10.1590/1678-4685-GMB-2019-0230 |
work_keys_str_mv | AT rahvarfarzaneh plasmagbp2promotermethylationisassociatedwithadvancedstagesinbreastcancer AT salimimahdieh plasmagbp2promotermethylationisassociatedwithadvancedstagesinbreastcancer AT mozdaranihossein plasmagbp2promotermethylationisassociatedwithadvancedstagesinbreastcancer |